{"id":"aatezolizumab-plus-bevacizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis)"},{"rate":null,"effect":"Bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Atezolizumab is a PD-L1 inhibitor that restores anti-tumor T-cell immunity by blocking the PD-L1/PD-1 checkpoint. Bevacizumab is a VEGF inhibitor that starves tumors of blood supply and may enhance immune infiltration. The combination leverages both immune checkpoint inhibition and anti-angiogenic mechanisms to improve anti-tumor efficacy.","oneSentence":"Atezolizumab blocks PD-L1 to enhance immune response while bevacizumab inhibits VEGF to reduce tumor angiogenesis, combining immunotherapy with anti-angiogenic therapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:20:15.361Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (Phase 2)"},{"name":"Advanced or metastatic solid tumors (Phase 2)"}]},"trialDetails":[{"nctId":"NCT04954339","phase":"PHASE2","title":"DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tae Won Kim","startDate":"2021-10-29","conditions":"Hepatocellular Carcinoma","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":216,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ticentriq plus Avastin"],"phase":"phase_2","status":"active","brandName":"Aatezolizumab plus Bevacizumab","genericName":"Aatezolizumab plus Bevacizumab","companyName":"Tae Won Kim","companyId":"tae-won-kim","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atezolizumab blocks PD-L1 to enhance immune response while bevacizumab inhibits VEGF to reduce tumor angiogenesis, combining immunotherapy with anti-angiogenic therapy. Used for Hepatocellular carcinoma (Phase 2), Advanced or metastatic solid tumors (Phase 2).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}